ACTA1 and Hepatic fibrosis: MSC-exos single administration in the treatment of liver fibrosis showed the following effects: 1reduced collagen deposition and fibroplasia (Masson and Sirius red staining); 2slowed down the progression of liver fibrosis (Ishak score, liver index, and α-SMA); 3improved liver function (AST, ALT, and ALP).